HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

被引：87

作者：

Papaccio, Federica ^{[1
]}

Della Corte, Carminia Maria ^{[1
]}

Viscardi, Giuseppe ^{[1
]}

Di Liello, Raimondo ^{[1
]}

Esposito, Giovanna ^{[1
]}

Sparano, Francesca ^{[1
]}

Ciardiello, Fortunato ^{[1
]}

Morgillo, Floriana ^{[1
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Sch Med, Dept Precis Med, Div Med Oncol, Via Pansini 5, I-80131 Naples, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 11期

关键词：

HGF; MET; immune system; cancer; immunotherapy; HEPATOCYTE GROWTH-FACTOR; C-MET; TYROSINE KINASE; T-CELLS; TUMOR MICROENVIRONMENT; SOMATIC MUTATIONS; DENDRITIC CELLS; FACTOR-RECEPTOR; SCATTER-FACTOR; DOUBLE-BLIND;

D O I：

10.3390/ijms19113595

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.

引用

页数：13

共 92 条

[31] Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy [J].

Glodde, Nicole ;

Bald, Tobias ;

van den Boorn-Konijnenberg, Debby ;

Nakamura, Kyohei ;

O'Donnell, Jake S. ;

Szczepanski, Sabrina ;

Brandes, Maria ;

Eickhoff, Sarah ;

Das, Indrajit ;

Shridhar, Naveen ;

Hinze, Daniel ;

Rogava, Meri ;

van der Sluis, Tetje C. ;

Ruotsalainen, Janne J. ;

Gaffal, Evelyn ;

Landsberg, Jennifer ;

Ludwig, Kerstin U. ;

Wilhelm, Christoph ;

Riek-Burchardt, Monika ;

Mueller, Andreas J. ;

Gebhardt, Christoffer ;

Scolyer, Richard A. ;

Long, Georgina V. ;

Janzen, Viktor ;

Teng, Michele W. L. ;

Kastenmueller, Wolfgang ;

Mazzone, Massimiliano ;

Smyth, Mark J. ;

Tueting, Thomas ;

Hoelzel, Michael .

IMMUNITY, 2017, 47 (04) :789-+

[32] Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations [J].

Gong, Jun ;

Chehrazi-Raffle, Alexander ;

Reddi, Srikanth ;

Salgia, Ravi .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[33] Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors [J].

Gordon, Michael S. ;

Sweeney, Christopher J. ;

Mendelson, David S. ;

Eckhardt, S. Gail ;

Anderson, Abraham ;

Beaupre, Darrin M. ;

Branstetter, Daniel ;

Burgess, Teresa L. ;

Coxon, Angela ;

Deng, Hongjie ;

Kaplan-Lefko, Paula ;

Leitch, Ian M. ;

Oliner, Kelly S. ;

Yan, Lucy ;

Zhu, Min ;

Gore, Lia .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :699-710

[34] FDA regulation of stem-cell-based therapies [J].

Halme, Dina Gould ;

Kessler, David A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16) :1730-1735

[35] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[36] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[37] The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma [J].

Herrera, LJ ;

El-Hefnawy, T ;

de Oliveira, PEQ ;

Raja, S ;

Finkelstein, S ;

Gooding, W ;

Luketich, JD ;

Godfrey, TE ;

Hughes, SJ .

NEOPLASIA, 2005, 7 (01) :75-84

[38] Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype [J].

Hilkens, CMU ;

Kalinski, P ;

deBoer, M ;

Kapsenberg, ML .

BLOOD, 1997, 90 (05) :1920-1926

[39] Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer [J].

Hirsch, Fred R. ;

Govindan, Ramaswamy ;

Zvirbule, Zanete ;

Braiteh, Fadi ;

Rittmeyer, Achim ;

Belda-Iniesta, Cristobal ;

Isla, Dolores ;

Cosgriff, Thomas ;

Boyer, Michelle ;

Ueda, Masamichi ;

Phan, See ;

Gandara, David R. .

CLINICAL LUNG CANCER, 2017, 18 (01) :43-49

[40] The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions [J].

Ilangumaran, Subburaj ;

Villalobos-Hernandez, Alberto ;

Bobbala, Diwakar ;

Ramanathan, Sheela .

CYTOKINE, 2016, 82 :125-139

← 1 2 3 4 5 6 7 8 9 10 →